The US Department of Health and Human Services Office of Inspector General (HHS OIG) issued a Special Advisory Bulletin (SAB) concluding that pharmaceutical manufacturers’ direct-to-consumer (DTC) prescription drug sales/programs can be designed to present sufficiently low risk under the Anti-Kickback Statute (AKS)….
By: Morgan Lewis
By: Morgan Lewis
